These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


303 related items for PubMed ID: 7727669

  • 1. Successful treatment of New World cutaneous leishmaniasis with a combination of topical paromomycin/methylbenzethonium chloride and injectable meglumine antimonate.
    Soto J, Hernandez N, Mejia H, Grogl M, Berman J.
    Clin Infect Dis; 1995 Jan; 20(1):47-51. PubMed ID: 7727669
    [Abstract] [Full Text] [Related]

  • 2. Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study.
    Soto J, Fuya P, Herrera R, Berman J.
    Clin Infect Dis; 1998 Jan; 26(1):56-8. PubMed ID: 9455509
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis.
    Armijos RX, Weigel MM, Calvopiña M, Mancheno M, Rodriguez R.
    Acta Trop; 2004 Jul; 91(2):153-60. PubMed ID: 15234664
    [Abstract] [Full Text] [Related]

  • 4. [Successful topical treatment of chronic cutaneous leishmaniasis with paromomycin sulfate (15%) and methylbenzethonium chloride (12%)].
    Schallreuter KU, Lemke KR.
    Hautarzt; 1994 Nov; 45(11):783-6. PubMed ID: 7822205
    [Abstract] [Full Text] [Related]

  • 5. Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment of American cutaneous leishmaniasis: controlled study.
    Krause G, Kroeger A.
    Clin Infect Dis; 1999 Aug; 29(2):466-7. PubMed ID: 10476776
    [No Abstract] [Full Text] [Related]

  • 6. Combined suboptimal schedules of topical paromomycin, meglumine antimoniate and miltefosine to treat experimental infection caused by Leishmania (Viannia) braziliensis.
    de Morais-Teixeira E, Aguiar MG, Soares de Souza Lima B, Ferreira LA, Rabello A.
    J Antimicrob Chemother; 2015 Dec; 70(12):3283-90. PubMed ID: 26346991
    [Abstract] [Full Text] [Related]

  • 7. Parenteral aminosidine is not effective for Peruvian mucocutaneous leishmaniasis.
    Llanos-Cuentas A, Echevarria J, Seas C, Chang E, Cruz M, Alvarez E, Rosales E, Campos P, Bryceson A.
    Am J Trop Med Hyg; 2007 Jun; 76(6):1128-31. PubMed ID: 17556623
    [Abstract] [Full Text] [Related]

  • 8. Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate.
    Faghihi G, Tavakoli-kia R.
    Clin Exp Dermatol; 2003 Jan; 28(1):13-6. PubMed ID: 12558620
    [Abstract] [Full Text] [Related]

  • 9. Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major.
    Shazad B, Abbaszadeh B, Khamesipour A.
    Eur J Dermatol; 2005 Jan; 15(2):85-7. PubMed ID: 15757817
    [Abstract] [Full Text] [Related]

  • 10. Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala.
    Arana BA, Mendoza CE, Rizzo NR, Kroeger A.
    Am J Trop Med Hyg; 2001 Nov; 65(5):466-70. PubMed ID: 11716099
    [Abstract] [Full Text] [Related]

  • 11. [Effect of a hydrophilic formulation of topical paromomycin on cutaneous leishmaniasis among patients with contraindications for treatment with pentavalent antimonials].
    Santos AM, Noronha EF, Ferreira LA, Carranza-Tamayo CO, Cupolillo E, Romero GA.
    Rev Soc Bras Med Trop; 2008 Nov; 41(5):444-8. PubMed ID: 19009183
    [Abstract] [Full Text] [Related]

  • 12. Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis.
    Moosavi Z, Nakhli A, Rassaii S.
    Int J Dermatol; 2005 Dec; 44(12):1064-5. PubMed ID: 16409282
    [No Abstract] [Full Text] [Related]

  • 13. Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru.
    Miranda-Verástegui C, Llanos-Cuentas A, Arévalo I, Ward BJ, Matlashewski G.
    Clin Infect Dis; 2005 May 15; 40(10):1395-403. PubMed ID: 15844060
    [Abstract] [Full Text] [Related]

  • 14. A randomized clinical trial comparing oral azithromycin and meglumine antimoniate for the treatment of American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis.
    Krolewiecki AJ, Romero HD, Cajal SP, Abraham D, Mimori T, Matsumoto T, Juarez M, Taranto NJ.
    Am J Trop Med Hyg; 2007 Oct 15; 77(4):640-6. PubMed ID: 17978064
    [Abstract] [Full Text] [Related]

  • 15. Generic sodium stibogluconate is as safe and effective as branded meglumine antimoniate, for the treatment of tegumentary leishmaniasis in Isiboro Secure Park, Bolivia.
    Bermúdez H, Rojas E, Garcia L, Desjeux P, Dujardin JC, Boelaert M, Chappuis F.
    Ann Trop Med Parasitol; 2006 Oct 15; 100(7):591-600. PubMed ID: 16989685
    [Abstract] [Full Text] [Related]

  • 16. Clinical efficacy of intramuscular meglumine antimoniate alone and in combination with intralesional meglumine antimoniate in the treatment of old world cutaneous leishmaniasis.
    Munir A, Janjua SA, Hussain I.
    Acta Dermatovenerol Croat; 2008 Oct 15; 16(2):60-4. PubMed ID: 18541100
    [Abstract] [Full Text] [Related]

  • 17. Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (Aminosidine) and gentamicin.
    Grogl M, Schuster BG, Ellis WY, Berman JD.
    J Parasitol; 1999 Apr 15; 85(2):354-9. PubMed ID: 10219319
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania viannia species.
    Palacios R, Osorio LE, Grajalew LF, Ochoa MT.
    Am J Trop Med Hyg; 2001 Apr 15; 64(3-4):187-93. PubMed ID: 11442216
    [Abstract] [Full Text] [Related]

  • 20. Use of topical rSm29 in combination with intravenous meglumine antimoniate in the treatment of cutaneous leishmaniasis: A randomized controlled trial.
    Lago T, Peixoto F, Mambelli F, Carvalho LP, Guimarães LH, Carvalho AM, Cardoso L, Machado PRL, Scott P, Lago J, Andrade JM, Fahel JS, Oliveira SC, Carvalho EM.
    Int J Infect Dis; 2024 Oct 15; 147():107206. PubMed ID: 39147194
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 16.